Article Figures & Data
Figures
- Figure 1.
Clinical outcomes after treatment with BRAFi±MEKi in V600E (red) and V600K (blue) metastatic melanoma. A, Best change in RECIST target lesions (%). B, PFS. C, OS.
- Figure 2.
Differences in gene expression between V600E and V600K melanoma. A, Differentially expressed genes (Nanostring data from BRAFi±MEKi cohort). Unadjusted P values: ⇐0.05 (light turquoise blue) and >0.05 (dark cadet blue). The top 10 differentially expressed genes are labeled (navy blue). B, Validation of increased DUSP6 expression in V600E melanomas (TCGA data). DESeq2 P value: 1.329e−05. DESeq2 adj. P value: 0.002843. Each dot/triangle represents one single sample.
- Figure 3.
Mutational load in V600E (red) and V600K (blue) melanoma. NGS data from BRAFi±MEKi cohort (A) and TCGA (B) data. Each dot/triangle represents one single sample.
- Figure 4.
Clinical outcomes after treatment with anti–PD-1 immunotherapy in V600E (red) and V600K (blue) metastatic melanoma. A, Best change in RECIST targets (%). B, PFS. C, OS.
Tables
- Table 1.
Baseline characteristics of patients with V600E versus V600K metastatic melanoma (BRAFi±MEKi cohort)
Characteristics V600E (n = 78) V600K (n = 15) P value Age (years) Median 56.5 58.0 0.418 Gender (N, %) 0.5786 Female 33 (42%) 5 (33%) Male 45 (58%) 10 (67%) AJCC stagea (N, %) 1 IIIC–M1b 19 (24%) 3 (20%) M1c 59 (76%) 12 (80%) LDH (N, %) 0.3563 Normal 57 (73%) 9 (60%) Elevated 21 (27%) 6 (40%) ECOG (N, %) 1 0 47 (60%) 9 (60%) ≥1 31 (40%) 6 (40%) Treatment (N, %) 0.3162 BRAFi 62 (80%) 10 (67%) BRAFi + MEKi 16 (20%) 5 (33%) ↵aAJCC v7 anatomic staging, excluding LDH and brain metastases.
- Table 2.
Baseline characteristics of patients with V600E versus V600K metastatic melanoma (immunotherapy cohort)
Characteristics V600E (n = 84) V600K (n = 19) P value Age (years) Median 51 61.5 0.0358 Gender (N, %) 0.001 Female 41 (49%) 3 (16%) Male 43 (51%) 16 (84%) AJCC stagea (N, %) 0.7571 IIIC–M1b 18 (21%) 3 (16%) M1c 66 (79%) 16 (84%) LDH (N, %) 0.1195 Normal 49 (58%) 15 (79%) Elevated 35 (42%) 4 (21%) ECOG (N, %) 0.2037 0 42 (50%) 13 (68%) ≥1 42 (50%) 6 (32%) Prior MAPKi (N, %) 0.8042 No 47 (56%) 11 (58%) Yes 37 (44%) 8 (42%) PD1 therapy (N, %) 0.0229 Nivolumab 22 2 Pembrolizumab 62 17 ↵aAJCC v7 anatomic staging, excluding LDH and brain metastases.
Volume 25, Issue 4
